Initial clinical trial of a novel hemostat, XXXX , in the endoscopic treatments of the @entity356 .

@entity1 @entity356 @entity38816 @entity548
BACKGROUND AND AIM: The feasibility of @entity38816 , the synthetic infectious agent-free peptides, was tested in hemostasis of the @entity548 after endoscopic treatments of the @entity356 . METHODS: The @entity1 who underwent endoscopic mucosal resection (EMR) or endoscopic submucosal dissection (ESD) were enrolled in the present study. The subject of hemostasis was the oozing after the EMR or ESD. The hemostatic effect, the secondary @entity548 from one postoperative day to the day before discharge and operability were studied. RESULTS: The hemostatic effects were assessed in 12 @entity1 . It was "remarkably effective" in 11 @entity1 and "effective" in 1 @entity1 . The operability was "very easy" in two @entity1 , "easy" in eight @entity1 and "acceptable" in two @entity1 . No secondary @entity548 was observed in all of 12 @entity1 . No adverse effect considered to be related to @entity38816 was observed. CONCLUSION: It was shown that hemostasis using @entity38816 was feasible after endoscopic treatments of the @entity356 without any technical trouble or adverse event.
